Bristol-Myers Squibb Company (BMY)
NYSE · Healthcare
Bristol-Myers Squibb Company Long Term Debt 2007–2025
Bristol-Myers Squibb Company annual long term debt history from 2008 to 2025. Long term debt refers to financial obligations that are due more than one year in the future.
- Bristol-Myers Squibb Company long term debt as of December 31, 2025: 44.83B, a 9.31% decrease year-over-year.
- Bristol-Myers Squibb Company long term debt for 2025 were 44.83B, a 9.31% decrease from 2024.
- Bristol-Myers Squibb Company long term debt for 2024 were 49.43B, a 25.06% increase from 2023.
- Bristol-Myers Squibb Company long term debt for 2023 were 39.53B, a 1.47% increase from 2022.
- Bristol-Myers Squibb Company long term debt for 2022 were 38.95B.
Long Term Debt
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Bristol-Myers Squibb Company Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2025 | $44,827 |
| 2024 | $49,431 |
| 2023 | $39,526 |
| 2022 | $38,953 |
| 2021 | $44,369 |
| 2020 | $50,336 |
| 2019 | $46,150 |
| 2018 | $6,895 |
| 2017 | $6,975 |
| 2016 | $5,716 |
| 2015 | $6,550 |
| 2014 | $7,242 |
| 2013 | $7,981 |
| 2012 | $7,232 |
| 2011 | $5,376 |
Bristol-Myers Squibb Company Long Term Debt — FAQ
Bristol-Myers Squibb Company (BMY) long term debt over the last 19 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BMY's long term debt history?
The chart and table above show Bristol-Myers Squibb Company's long term debt by year and by quarter, including the growth rate.